NCT01472991 - Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD) | Biotech Hunter

Enrollment

250

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG

TC-5619-238 5mg

TC-5619-238 5mg capsule taken once daily for 4 weeks

DRUG

TC-5619-238 25mg

TC-5619-238 25mg capsules taken once daily for 4 weeks

DRUG

Placebo

Placebo capsules will be taken once daily for 4 weeks

Trial Locations (14)

32216

Clinical Neuroscience Solutions, Inc., Jacksonville

32751

Florida Clinical Research Center, LLC, Maitland

32806

Clinical Neuroscience Solutions, Inc., Orlando

Compass Research, Inc., Orlando

Compass Research, LLC, Orlando

34201

Florida Clinical Research Center, LLC, Bradenton

38119

CNS Healthcare, Memphis

44718

Neuro-Behavioral Clinical Reseach, Inc., Canton

45417

Midwest Clinical Research Center, Dayton

78731

FutureSearch Clinical Trials, LP, Austin

80910

MCB Clinical Research Centers, LLC, Colorado Springs

90210

Southwestern Research, Inc, Beverly Hills

91920

Synergy Clinical Research Center, National City

02114

Clinical Trials Network & Institute, Massachusetts General Hospital, Boston

All Listed Sponsors

lead

Targacept Inc.

INDUSTRY